Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Monday,Benzinga reports. They currently have a $24.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on AVXL. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, February 10th. Wall Street Zen raised Anavex Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Anavex Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $22.00.

Anavex Life Sciences Trading Down 34.6%

AVXL stock opened at $2.74 on Monday. The stock has a 50-day moving average price of $4.47 and a two-hundred day moving average price of $5.71. The stock has a market cap of $253.92 million, a PE ratio of -5.96 and a beta of 1.08. Anavex Life Sciences has a 1 year low of $2.61 and a 1 year high of $13.99.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. On average, analysts forecast that Anavex Life Sciences will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AVXL. State Street Corp grew its stake in Anavex Life Sciences by 33.4% in the fourth quarter. State Street Corp now owns 4,383,406 shares of the biotechnology company’s stock valued at $15,605,000 after purchasing an additional 1,096,288 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Anavex Life Sciences by 17,921.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 744,469 shares of the biotechnology company’s stock worth $2,650,000 after purchasing an additional 740,338 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Anavex Life Sciences by 187.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 872,968 shares of the biotechnology company’s stock worth $3,108,000 after purchasing an additional 569,579 shares in the last quarter. Summit Financial LLC boosted its holdings in shares of Anavex Life Sciences by 103.3% in the 4th quarter. Summit Financial LLC now owns 903,392 shares of the biotechnology company’s stock valued at $3,216,000 after buying an additional 459,121 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of Anavex Life Sciences in the fourth quarter valued at $1,310,000. 31.55% of the stock is owned by institutional investors and hedge funds.

More Anavex Life Sciences News

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: D. Boral Capital reiterated a “Buy” rating on AVXL, which could provide some analyst support and steady investor conviction despite the regulatory setback. D. Boral Capital Reiterates “Buy” Rating for Anavex Life Sciences
• Neutral Sentiment: Company statement: Anavex issued a formal press release confirming it withdrew the EU application after CHMP feedback; this is factual disclosure but does not yet explain remedial steps or a resubmission timeline. Investors should watch for follow-up on whether Anavex will seek additional data, meetings with EMA, or a revised submission plan. Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine
• Neutral Sentiment: Short-interest reports in recent filings appear inconsistent/erroneous (showing 0 shares and NaN changes); current public short-interest data may not reliably reflect actual positioning — monitor reliable 13F/market reports for clearer short activity. (multiple market-data entries)
• Negative Sentiment: Regulatory setback and market coverage: Multiple outlets report that AVXL withdrew its EU filing after EMA/CHMP pushback; coverage frames this as a material negative that prompted heavy selling and a sharp intraday drop, increasing uncertainty about near-term commercialization in Europe. Anavex Life Sciences Stock Crushed As European Alzheimer’s Drug Filing Pulled After EMA Pushback Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.